Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis

Edit Végh, György Kerekes, Anita Pusztai, Attila Hamar, Szilvia Szamosi, Andrea Váncsa, Levente Bodoki, Lilla Pogácsás, Fruzsina Balázs, Katalin Hodosi, Andrea Domján, Sándor Szántó, Zoltán Nagy, Zoltán Szekanecz, Gabriella Szűcs

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Accelerated atherosclerosis, increased cardiovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Vascular function, clinical and laboratory markers and the effects of anti-TNF therapy were assessed in arthritides. Fifty-three 53 patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. A significant improvement of brachial artery FMD was observed after 6 months (p = 0.004). A tendency of FMD improvement was also observed after 12 months (p = 0.065). ccIMT did not change throughout the year. PWV significantly improved after 12 months (p = 0.034). Higher baseline ccIMT (p = 0.009) and PWV (p = 0.038) were associated with clinical non-response (cNR) versus response (cR) to biologics. Multiple analysis confirmed the association of baseline ccIMT with age (p = 0.003) and cNR (p = 0.009), as well as that of baseline PWV with age at diagnosis (p = 0.022) and current chest pain (p = 0.004). Treatment itself determined the 12-month changes in FMD (p = 0.020) and PWV (p = 0.007). In a mixed cohort of RA and AS patients, TNF inhibition improved or stabilized vascular pathophysiology. Inflammation may be associated with FMD, while, among others, cNR may influence vascular function.

Original languageEnglish
JournalRheumatology International
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Pulse Wave Analysis
Ankylosing Spondylitis
Carotid Intima-Media Thickness
Vasodilation
Blood Vessels
Rheumatoid Arthritis
Biomarkers
Therapeutics
Brachial Artery
Biological Products
Chest Pain
Arthritis
Ultrasonography
Atherosclerosis
Inflammation
Morbidity
Mortality

Keywords

  • Ankylosing spondylitis
  • Atherosclerosis
  • Cardiovascular disease
  • Carotid intima-media thickness
  • Flow-mediated vasodilation
  • Pulse-wave velocity
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. / Végh, Edit; Kerekes, György; Pusztai, Anita; Hamar, Attila; Szamosi, Szilvia; Váncsa, Andrea; Bodoki, Levente; Pogácsás, Lilla; Balázs, Fruzsina; Hodosi, Katalin; Domján, Andrea; Szántó, Sándor; Nagy, Zoltán; Szekanecz, Zoltán; Szűcs, Gabriella.

In: Rheumatology International, 01.01.2019.

Research output: Contribution to journalArticle

Végh, E, Kerekes, G, Pusztai, A, Hamar, A, Szamosi, S, Váncsa, A, Bodoki, L, Pogácsás, L, Balázs, F, Hodosi, K, Domján, A, Szántó, S, Nagy, Z, Szekanecz, Z & Szűcs, G 2019, 'Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis', Rheumatology International. https://doi.org/10.1007/s00296-019-04497-0
Végh, Edit ; Kerekes, György ; Pusztai, Anita ; Hamar, Attila ; Szamosi, Szilvia ; Váncsa, Andrea ; Bodoki, Levente ; Pogácsás, Lilla ; Balázs, Fruzsina ; Hodosi, Katalin ; Domján, Andrea ; Szántó, Sándor ; Nagy, Zoltán ; Szekanecz, Zoltán ; Szűcs, Gabriella. / Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. In: Rheumatology International. 2019.
@article{2397912a81044940b2924d967a8752cc,
title = "Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis",
abstract = "Accelerated atherosclerosis, increased cardiovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Vascular function, clinical and laboratory markers and the effects of anti-TNF therapy were assessed in arthritides. Fifty-three 53 patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. A significant improvement of brachial artery FMD was observed after 6 months (p = 0.004). A tendency of FMD improvement was also observed after 12 months (p = 0.065). ccIMT did not change throughout the year. PWV significantly improved after 12 months (p = 0.034). Higher baseline ccIMT (p = 0.009) and PWV (p = 0.038) were associated with clinical non-response (cNR) versus response (cR) to biologics. Multiple analysis confirmed the association of baseline ccIMT with age (p = 0.003) and cNR (p = 0.009), as well as that of baseline PWV with age at diagnosis (p = 0.022) and current chest pain (p = 0.004). Treatment itself determined the 12-month changes in FMD (p = 0.020) and PWV (p = 0.007). In a mixed cohort of RA and AS patients, TNF inhibition improved or stabilized vascular pathophysiology. Inflammation may be associated with FMD, while, among others, cNR may influence vascular function.",
keywords = "Ankylosing spondylitis, Atherosclerosis, Cardiovascular disease, Carotid intima-media thickness, Flow-mediated vasodilation, Pulse-wave velocity, Rheumatoid arthritis",
author = "Edit V{\'e}gh and Gy{\"o}rgy Kerekes and Anita Pusztai and Attila Hamar and Szilvia Szamosi and Andrea V{\'a}ncsa and Levente Bodoki and Lilla Pog{\'a}cs{\'a}s and Fruzsina Bal{\'a}zs and Katalin Hodosi and Andrea Domj{\'a}n and S{\'a}ndor Sz{\'a}nt{\'o} and Zolt{\'a}n Nagy and Zolt{\'a}n Szekanecz and Gabriella Szűcs",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00296-019-04497-0",
language = "English",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis

AU - Végh, Edit

AU - Kerekes, György

AU - Pusztai, Anita

AU - Hamar, Attila

AU - Szamosi, Szilvia

AU - Váncsa, Andrea

AU - Bodoki, Levente

AU - Pogácsás, Lilla

AU - Balázs, Fruzsina

AU - Hodosi, Katalin

AU - Domján, Andrea

AU - Szántó, Sándor

AU - Nagy, Zoltán

AU - Szekanecz, Zoltán

AU - Szűcs, Gabriella

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Accelerated atherosclerosis, increased cardiovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Vascular function, clinical and laboratory markers and the effects of anti-TNF therapy were assessed in arthritides. Fifty-three 53 patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. A significant improvement of brachial artery FMD was observed after 6 months (p = 0.004). A tendency of FMD improvement was also observed after 12 months (p = 0.065). ccIMT did not change throughout the year. PWV significantly improved after 12 months (p = 0.034). Higher baseline ccIMT (p = 0.009) and PWV (p = 0.038) were associated with clinical non-response (cNR) versus response (cR) to biologics. Multiple analysis confirmed the association of baseline ccIMT with age (p = 0.003) and cNR (p = 0.009), as well as that of baseline PWV with age at diagnosis (p = 0.022) and current chest pain (p = 0.004). Treatment itself determined the 12-month changes in FMD (p = 0.020) and PWV (p = 0.007). In a mixed cohort of RA and AS patients, TNF inhibition improved or stabilized vascular pathophysiology. Inflammation may be associated with FMD, while, among others, cNR may influence vascular function.

AB - Accelerated atherosclerosis, increased cardiovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Vascular function, clinical and laboratory markers and the effects of anti-TNF therapy were assessed in arthritides. Fifty-three 53 patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. A significant improvement of brachial artery FMD was observed after 6 months (p = 0.004). A tendency of FMD improvement was also observed after 12 months (p = 0.065). ccIMT did not change throughout the year. PWV significantly improved after 12 months (p = 0.034). Higher baseline ccIMT (p = 0.009) and PWV (p = 0.038) were associated with clinical non-response (cNR) versus response (cR) to biologics. Multiple analysis confirmed the association of baseline ccIMT with age (p = 0.003) and cNR (p = 0.009), as well as that of baseline PWV with age at diagnosis (p = 0.022) and current chest pain (p = 0.004). Treatment itself determined the 12-month changes in FMD (p = 0.020) and PWV (p = 0.007). In a mixed cohort of RA and AS patients, TNF inhibition improved or stabilized vascular pathophysiology. Inflammation may be associated with FMD, while, among others, cNR may influence vascular function.

KW - Ankylosing spondylitis

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Carotid intima-media thickness

KW - Flow-mediated vasodilation

KW - Pulse-wave velocity

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85076506887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076506887&partnerID=8YFLogxK

U2 - 10.1007/s00296-019-04497-0

DO - 10.1007/s00296-019-04497-0

M3 - Article

AN - SCOPUS:85076506887

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

ER -